These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 33979868)

  • 41. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
    Carhart-Harris RL; Goodwin GM
    Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.
    Ona G; Bouso JC
    Neurosci Biobehav Rev; 2020 Dec; 119():194-203. PubMed ID: 33031815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20
    Aday JS; Bloesch EK; Davoli CC
    J Psychoactive Drugs; 2019; 51(3):210-217. PubMed ID: 30836890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
    Greenway KT; Garel N; Jerome L; Feduccia AA
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):655-670. PubMed ID: 32478631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
    Sekula AD; Downey L; Puspanathan P
    Front Psychol; 2022; 13():813746. PubMed ID: 35310225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychedelic Medicines in Major Depression: Progress and Future Challenges.
    Bouso JC; Ona G; Dos Santos RG; Hallak JEC
    Adv Exp Med Biol; 2021; 1305():515-533. PubMed ID: 33834416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
    Weleff J; Akiki TJ; Barnett BS
    J Psychoactive Drugs; 2023; 55(4):434-444. PubMed ID: 36218281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics.
    Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S
    J Psychoactive Drugs; 2023; 55(1):1-10. PubMed ID: 35000572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.